Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

Neuren and Acadia have previously reported positive results in a phase 2 trial in patients with Rett Syndrome. According to a press release issued by Neuren toda,y Acadia will be initiating Phase 3 trials in the near term. Question: If Australian regulators haven't seen fit to accelerate approval or provide conditional approval of trofinetide based on its positive safety and efficacy data (keeping in mind that Neuren is an Australian company and you would think Australian regulators would favor a local company), why does anyone think that Australian regulators would accelerate approval, or provide conditional approval, of blarcamesine?